InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, releases an integration of CYTOCON DB and fIVE DB with Heta. Now Heta format is upgraded to allow direct query to databases from the QSP model code without working with database websites.
CYTOCON DB is an online database of human baseline concentrations of cytokines and cells measured in different tissues of healthy subjects and patients suffering from various pathologies. Heta format developed for QSP models encoding into Excel table was upgraded in such a way to allow results of the query to CYTOCON DB to appear in the QSP model code directly in the section describing species included in the model in form of weighted mean and weighted standard deviations for cells and cytokines concentrations. Moreover, results of the query to fIVE DB now appear in the QSP model code directly in the section describing initialization of model parameters in form of weighted mean and minimal and maximal values of model parameters (kbase, Emax/IC50, EC50/IC50, etc.) fIVE DB is an InSysBio project for in vitro experiments information collection and processing.
Such integration of CYTOCON DB and fIVE DB with Heta enables QSP modelers:
About Heta
The Heta Project is an open-source initiative dedicated to transforming the landscape of pharmacology and systems biology modeling. By developing a unified infrastructure and best practices, we empower researchers and practitioners to create dynamic quantitative models with ease and efficiency. Heta is a software tool for the development of large-scale QSP models and compilation into simulation formats.
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | August 2020 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
| |||||
|
3
1.
03 Aug 2020 16:00
InSysBio to share new data in frames of its Open Source QSP model of COVID-19
InSysBio has received a new set of results in framework of development of QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
|
4
|
5
|
6
1.
06 Aug 2020 17:51
InSysBio to update its Cytocon DB and to present version 1.2.6.6
InSysBio is glad to present Cytocon DB 1.2.6.6! Cytocon DB team has reviewed 39 articles to introduce new data. It should be outlined that the total number of concentrations within the Database has already exceeded 10 thousand!
|
7
|
8
|
9
|
|
10
|
11
|
12
|
13
|
14
|
15
|
16
|
|
17
|
18
|
19
|
20
1.
20 Aug 2020 17:18
InSysBio to present the new version of Immune Response Template
IRT 3.2.0 acquires new models and extended annotations
(Moscow – 20.08.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, presents the new version of its Immune Response Template (IRT). IRT is an efficient and useful tool to boost and facilitate the development of QSP models in immunology and immuno-oncology therapeutic areas. By this point IRT has been developed into a fully-fledged database but InSysBio constantly goes further in its software advancement.
|
21
|
22
|
23
|
|
24
|
25
|
26
|
27
|
28
|
29
|
30
|
|
31
| ||||||
Thank you for your message! We will get back to you shortly.
